Dual-drug delivery by porous silicon nanoparticles for improved cellular uptake, sustained release, and combination therapy

Acta Biomaterialia

Volumn 16, Issue 1, 2015, Pages 206-214

  Wang, Chang Fang ^a   Mäkilä, Ermei M ^a,b   Kaasalainen, Martti H ^b   Hagström, Marja V ^a   Salonen, Jarno J ^b   Hirvonen, Jouni T ^a   Santos, Hélder A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Combination therapy; Intracellular uptake; Methotrexate Sorafenib; Porous silicon nanoparticles; Sustained drug release

Indexed keywords

CELL DEATH; CELL PROLIFERATION; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DISEASES; DISSOLUTION; DRUG PRODUCTS; HIGH RESOLUTION TRANSMISSION ELECTRON MICROSCOPY; HYDROPHOBICITY; MASS SPECTROMETRY; NANOPARTICLES; SILICON COMPOUNDS; TARGETED DRUG DELIVERY;

CANCER CELLS; CELLULAR UPTAKE; COMBINATION THERAPY; FOLATE RECEPTOR; INTRACELLULAR UPTAKE; METHOTREXATE/SORAFENIB; POROUS SILICON NANOPARTICLE; SILICON NANOPARTICLES; SORAFENIB; SUSTAINED DRUG RELEASE;

POROUS SILICON;

FOLATE RECEPTOR; METHOTREXATE; NANOPARTICLE; SILICON; SILICON NANOPARTICLE; UNCLASSIFIED DRUG; CARBANILAMIDE DERIVATIVE; DELAYED RELEASE FORMULATION; NICOTINAMIDE; SORAFENIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG UPTAKE; ELECTROPHORETIC MOBILITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC50; INTERNALIZATION; LIGHT SCATTERING; MASS SPECTROMETRY; PH; PHARMACEUTICAL CARE; POROSITY; PRIORITY JOURNAL; SURFACE AREA; SUSTAINED DRUG RELEASE; TUMOR GROWTH; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; ENDOCYTOSIS; INFRARED SPECTROSCOPY; MULTIMODALITY CANCER THERAPY; PARTICLE SIZE; STATIC ELECTRICITY; TUMOR CELL LINE; ULTRASTRUCTURE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; METHOTREXATE; NANOPARTICLES; NIACINAMIDE; PARTICLE SIZE; PHENYLUREA COMPOUNDS; POROSITY; SILICON; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STATIC ELECTRICITY;

EID: 84930940792     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2015.01.021     Document Type: Article

References (50)

1. van der Meel R, Vehmeijer LJ, Kok RJ, Storm G, van Gaal EV. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv Drug Deliv Rev 2013;65:1284-98.
2. Shahbazi MA, Hamidi M, Mäkilä EM, Zhang H, Almeida PV, Kaasalainen M, et al. The mechanisms of surface chemistry effects of mesoporous silicon nanoparticles on immunotoxicity and biocompatibility. Biomaterials 2013;34:7776-89.
3. Bimbo LM, Denisova OV, Mäkilä E, Kaasalainen M, De Brabander JK, Hirvonen J, et al. Inhibition of influenza a virus infection in vitro by saliphenylhalamide-loaded porous silicon nanoparticles. ACS Nano 2013;7:6884-93.
4. Bimbo LM, Mäkilä E, Raula J, Laaksonen T, Laaksonen P, Strommer K, et al. Functional hydrophobin-coating of thermally hydrocarbonized porous silicon microparticles. Biomaterials 2011;32:9089-99.
5. Liu D, Bimbo LM, Mäkilä E, Villanova F, Kaasalainen M, Herranz-Blanco B, et al. Co-delivery of a hydrophobic small molecule and a hydrophilic peptide by porous silicon nanoparticles. J Control Release 2013;170:268-78.
6. Sarparanta MP, Bimbo LM, Mäkilä EM, Salonen JJ, Laaksonen PH, Helariutta AM, et al. The mucoadhesive and gastroretentive properties of hydrophobincoated porous silicon nanoparticle oral drug delivery systems. Biomaterials 2012;33:3353-62.
7. Santos HA, Riikonen J, Salonen J, Mäkilä E, Heikkilä T, Laaksonen T, et al. In vitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size. Acta Biomater 2010;6:2721-31.
8. Mann AP, Tanaka T, Somasunderam A, Liu X, Gorenstein DG, Ferrari M. Eselectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv Mater 2011;23:H278-82.
9. Godin B, Gu J, Serda RE, Ferrati S, Liu X, Chiappini C, et al. Multistage mesoporous silicon-based nanocarriers: biocompatibility with immune cells and controlled degradation in physiological fluids. Control Release Newsl. 2008;25:9-11.
10. Tanaka T, Mangala LS, Vivas-Mejia PE, Nieves-Alicea R, Mann AP, Mora E, et al. Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res 2010;70:3687-96.
11. von Maltzahn G, Park JH, Lin KY, Singh N, Schwoppe C, Mesters R, et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater 2011;10:545-52.
12. Park JH, Gu L, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Biodegradable luminescent porous silicon nanoparticles for in vivo applications. Nat Mater 2009;8:331-6.
13. Salonen J, Laitinen L, Kaukonen AM, Tuura J, Bjorkqvist M, Heikkilä T, et al. Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J Control Release 2005;108:362-74.
14. Santos HA, Bimbo LM, Lehto VP, Airaksinen AJ, Salonen J, Hirvonen J. Multifunctional porous silicon for therapeutic drug delivery and imaging. Curr Drug Discov Technol 2011;8:228-49.
15. Jarvis KL, Barnes TJ, Prestidge CA. Surface chemical modification to control molecular interactions with porous silicon. J Colloid Interface Sci 2011;363:327-33.
16. Kinnari PJ, Hyvonen ML, Mäkilä EM, Kaasalainen MH, Rivinoja A, Salonen JJ, et al. Tumour homing peptide-functionalized porous silicon nanovectors for cancer therapy. Biomaterials 2013;34:9134-41.
17. Wang CF, Mäkilä EM, Kaasalainen MH, Liu D, Sarparanta MP, Airaksinen AJ, et al. Copper-free azide-alkyne cycloaddition of targeting peptides to porous silicon nanoparticles for intracellular drug uptake. Biomaterials 2014;35:1257-66.
18. Wu EC, Andrew JS, Cheng L, Freeman WR, Pearson L, Sailor MJ. Real-time monitoring of sustained drug release using the optical properties of porous silicon photonic crystal particles. Biomaterials 2011;32:1957-66.
19. Mäkilä E, Bimbo LM, Kaasalainen M, Herranz B, Airaksinen AJ, Heinonen M, et al. Amine modification of thermally carbonized porous silicon with silane coupling chemistry. Langmuir 2012;28:14045-54.
20. Ryser HJ, Shen WC. Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc Natl Acad Sci USA 1978;75:3867-70.
21. Jiang T, Li YM, Lv Y, Cheng YJ, He F, Zhuo RX. Amphiphilic polycarbonate conjugates of doxorubicin with pH-sensitive hydrazone linker for controlled release. Colloids Surf B Biointerfaces 2013;10:542-8.
22. Gonen N, Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 2012;15:183-210.
23. Neradil J, Pavlasova G, Veselska R. New mechanisms for an old drug; DHFRand non-DHFR-mediated effects of methotrexate in cancer cells. Klin Onkol 2012;25:2S87-92.
24. Barton AK, Antoieta C. Receptor-mediated folate accumulation is regulated by the cellular folate content.pdf. Proc Natl Acad Sci USA 1986;83:5983-7.
25. Zwicke GL, Mansoori GA, Jeffery CJ. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev 2012;3:18496.
26. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-93.
27. Bertino JR, Göker E, Gorlick R, Li WW, Banerjee D. Resistance mechanisms to methotrexate in tumors. Stem Cells 1996;14:5-9.
28. Chen J, Huang L, Lai H, Lu C, Fang M, Zhang Q, et al. Methotrexate-loaded PEGylated chitosan nanoparticles: synthesis, characterization, and in vitro and in vivo antitumoral activity. Mol Pharmaceutics 2014;11:2213-23.
29. Gurdag S, Khandare J, Stapels S, Matherly LH, Kannan RM. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and - resistant cell lines. Bioconjug Chem 2006;17:275-83.
30. Kaminskas LM, Kelly BD, McLeod VM, Boyd BJ, Krippner GY, Williams ED, et al. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-L-lysine dendrimers. Mol Pharmaceutics 2009;6:1190-204.
31. Thomas TP, Huang B, Choi SK, Silpe JE, Kotlyar A, Desai AM, et al. Polyvalent dendrimer-methotrexate as a folate receptor-targeted cancer therapeutic. Mol Pharmaceutics 2012;9:2669-76.
32. Huang B, Otis J, Joice M, Kotlyar A, Thomas TP. PSMA-targeted stably-linked 'dendrimer-glutamate urea-methotrexate' as a prostate cancer therapeutic. Biomacromolecules 2014;15:915-23.
33. Kaminskas LM, Kelly BD, McLeod VM, Sberna G, Boyd BJ, Owen DJ, et al. Capping methotrexate alpha-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers. Mol Pharmaceutics 2011;8:338-49.
34. Majumdar S, Anderson ME, Xu CR, Yakovleva TV, Gu LC, Malefyt TR, et al. Methotrexate (MTX)-cIBR conjugate for targeting MTX to leukocytes: conjugate stability and in vivo efficacy in suppressing rheumatoid arthritis. J Pharm Sci 2012;101:3275-91.
35. Pica K, Tchao R, Ofner 3rd CM. Gelatin-methotrexate conjugate microspheres as a potential drug delivery system. J Pharm Sci 2006;95:1896-908.
36. Taheri A, Dinarvand R, Ahadi F, Khorramizadeh MR, Atyabi F. The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice. Int J Pharm 2012;431:183-9.
37. Kohler N, Sun C, Fichtenholtz A, Gunn J, Fang C, Zhang M. Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery. Small 2006;2:785-92.
38. Choi Y, Kim M, Cho Y, Yun E, Song R. Synthesis, characterization and target protein binding of drug-conjugated quantum dots in vitro and in living cells. Nanotechnology 2013;24:075101.
39. Das M, Datir SR, Singh RP, Jain S. Augmented anticancer activity of a targeted, intracellularly activatable, theranostic nanomedicine based on fluorescent and radiolabeled, methotrexate-folic acid-multiwalled carbon nanotube conjugate. Mol Pharmaceutics 2013;10:2543-57.
40. Rosenholm JM, Peuhu E, Bate-Eya LT, Eriksson JE, Sahlgren C, Linden M. Cancer-cell-specific induction of apoptosis using mesoporous silica nanoparticles as drug-delivery vectors. Small 2010;6:1234-41.
41. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
42. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, Konopleva MY, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol J Am Soc Clin Oncol 2010;28:1856-62.
43. Moore M, Hirte HW, Siu L, Oza A, Hotte SJ, Petrenciuc O, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005;16:1688-94.
44. Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-37.
45. Bimbo LM, Mäkilä E, Laaksonen T, Lehto VP, Salonen J, Hirvonen J, et al. Drug permeation across intestinal epithelial cells using porous silicon nanoparticles. Biomaterials 2011;32:2625-33.
46. Cannon WR, Garrison BJ, Benkovic SJ. Consideration of the pH-dependent inhibition of dihydrofolate reductase by methotrexate. J Mol Biol 1997;271:656-68.
47. Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA 2008;105:11613-8.
48. Krasnici S, Werner A, Eichhorn ME, Schmitt-Sody M, Pahernik SA, Sauer B, et al. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 2003;105:561-7.
49. Kane MA, Portillo RM, Elwood PC, Antony AC, Kolhouse JF. The influence of extracellular folate concentration on methotrexate uptake by human KB cells. Partial characterization of a membrane-associated methotrexate binding protein. J Biol Chem 1986;261:44-9.
50. Rajagopalan PT, Zhang Z, McCourt L, Dwyer M, Benkovic SJ, Hammes GG. Interaction of dihydrofolate reductase with methotrexate: ensemble and single-molecule kinetics. Proc Natl Acad Sci USA 2002;99:13481-6.